CRT Plenary Group is composed of:
- ESC Board Members
- Industry representatives from the cardiovascular field who paid a membership fee to join (2 representatives per company).
CRT Governance
The administration of the CRT is conducted by a group composed of Co-Chairs and Nucleus Members
CRT Co-Chairs: Job description
The CRT is co-chaired by an ESC and an industry representative:
- For the ESC, this is the President-Elect (2-year mandate)
- For industry, an election by the CRT Industry members for a 3-year mandate.
CRT Nucleus Members: Job description
This group oversees the CRT activities and is composed of:
- CRT Co-Chairs
- ESC Members appointed by the ESC Co-Chair (2-year mandate)
- The previous Industry Chair as Advisor
- 7 elected industry representatives from each industry sector (2-year mandate aligned with the ESC mandate); elected by the industry members
CRT Academic Members, mandate September 2024-August 2026
- Prof. Cecilia Linde : ESC President Elect and CRT Academic Chair, Sweden
- Dr. Christian John Fielder Camm, UK
- Prof. Filippo Crea, Italy
- Dr. Victoria Delgado, Spain
- Prof. Stefan James, Sweden
- Prof. Christophe Leclercq, France
- Prof. Felix Mahfoud, Switzerland
- Prof. Susanna Price, UK
- Prof. Piotr Szymanski, Poland
- Michael Madigan (Patient Forum representative)
- Mattias Van Heetvelde (Patient Forum representative)
CRT Industry Members, mandate 2024-2026
- Prof. Alexandra Goncalves: CRT Industry Chair (elected until August 2025) Bristol-Myers Squibb (BMS)
- Dr. Bettina Kraus: Boehringer Ingelheim Pharmaceuticals Inc (CRT Industry Chair starting Sep 2025- Aug 2028)
- Dr. Ola Vedin: AztraZeneca
- Mr. Andre Krueger: Novartis
- Dr. Sanjay Gandhi: Philips
- Dr. André Ziegler: Roche Diagnostics International Ltd.
Industry Co-Chair position
Since 2018, an election process has been established to appoint the Industry Co-Chair of the ESC Cardiovascular Round Table (CRT).
Professor Alexandra Goncalves was elected in 2022 for a three-year term that runs until August 2025.
Election Results:
We are pleased to announce, Dr. Bettina Kraus: Boehringer Ingelheim Pharmaceuticals Inc. has been elected and will start her mandate in September 2025 until August 2028
Our mission: To reduce the burden of cardiovascular disease.